YIGSR peptidomimetics and methods for using the same

A peptidomimetic compound comprising a substantially rigid non-peptidic, scaffold, tyrosine or a tyrosine-like group, isoleucine or an isoleucine-like group, serine or a serine-like group, and arginine or an arginine-like group, said substantially rigid non-peptidic scaffold positioning said groups in substantially the same manner as occurs in the peptide Tyr-Ile-Gly-Ser-Arg.

A peptidomimetic compound comprising the structure

• 69
• wherein A1- A8 comprise carbon or nitrogen, B1- B5comprise carbon, nitrogen, oxygen or sulfur, and wherein R1, R2, R3 and R4 respectively comprise arginine or an arginine-like group, tyrosine or a tyrosine-like group, isoleucine or an isoleucine-like group, and serine or a serine-like group.

A pharmaceutical preparation of a compound having a substantially rigid non-peptidic scaffold structure which mimics a binding site of Laminin Binding Protein.

A pharmaceutical preparation comprising a peptidomimetic compound having the structure

• 71
• wherein A1- A8 comprise carbon or nitrogen, B1-B5 comprise carbon, nitrogen, oxygen or sulfur, and wherein R1, R2, R3 and R4 respectively comprise arginine or an arginine-like group, tyrosine or a tyrosine-like group, isoleucine or an isoleucine-like group, and serine or a serine-like group.

A method for binding the Tyr-Ile-Gly-Ser-Arg binding site of Laminin Binding Protein, comprising contacting said binding site with a peptidomimetic compound comprising a substantially rigid non-peptidic scaffold, a tyrosine-like group, an isoleucine-like group, a serine-like group, and an arginine-like group, said substantially rigid non-peptidic scaffold positioning said tyrosine-like group, said isoleucine-like group, said serine-like group and said arginine-like group in substantially the same manner as occurs in the peptide Tyr-Ile-Gly-Ser-Arg.

A method for treating a subject suffering from a cellular proliferative disease, said method comprising:

• admininstering to said subject a therapeutically effective amount of a compound having a substantially rigid non-peptidic scaffold structure which mimics a binding site of Laminin Binding Protein.